SCHEDULE: Point72 Amends KalVista Stake Disclosure

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, filed an amended Schedule 13G to correct their beneficial ownership of KalVista Pharmaceuticals, Inc. common stock, now reporting a 5.5% stake.

Summary

• Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen filed an Amendment No. 1 to their Schedule 13G.
• The amendment corrects the beneficial ownership previously disclosed in the original Schedule 13G filed on January 12, 2026.
• The reporting persons collectively beneficially own 2,781,902 shares of KalVista Pharmaceuticals, Inc. common stock.
• This represents 5.5% of the class of securities.
• The ownership information is as of the close of business on January 9, 2026.
• Point72 Asset Management maintains investment and voting power over the securities held by Point72 Associates, an investment fund it manages.
• Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities.
• The securities were not acquired for the purpose of changing or influencing control of KalVista Pharmaceuticals, Inc.

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of beneficial ownership and an amendment to correct previously filed information. It does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects, but rather clarifies an ownership stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides clarity on a significant institutional ownership stake, correcting previous disclosure.

Key Dates

Keywords

KalVista Pharmaceuticals, Point72 Asset Management, Steven A. Cohen, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Ownership, Equity Stake, Amendment